Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Acute Inflammation I: Cellular Phase01:26

Acute Inflammation I: Cellular Phase

The cellular phase of acute inflammation is a tightly orchestrated sequence of events that recruits leukocytes, primarily neutrophils, to sites of tissue injury or infection. Following the initial vascular changes, this phase ensures effective immune cell migration, activation, and function at the affected site to eliminate pathogens and initiate tissue repair.Leukocyte Recruitment CascadeLeukocyte recruitment happens in four steps: margination, adhesion, transmigration, and chemotaxis. Reduced...
Asthma I: Introduction01:28

Asthma I: Introduction

Asthma is a chronic inflammatory disorder of the airways characterized by variable airflow obstruction and heightened bronchial responsiveness to a wide range of triggers. The underlying inflammation leads to airway swelling, mucus hypersecretion, and smooth muscle constriction, all of which narrow the airway lumen and impede airflow. Clinically, asthma presents with recurrent episodes of wheezing, shortness of breath, chest tightness, and coughing, symptoms that typically vary in intensity and...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Acute Inflammation I: Inflammatory Response01:26

Acute Inflammation I: Inflammatory Response

Acute inflammation is a rapid, short-lived physiological response to tissue injury or infection, designed to eliminate harmful agents and initiate repair. This tightly regulated process typically lasts from minutes to several days and is triggered by factors such as microbial invasion, physical trauma, or chemical injury.Recognition and Mediator ReleaseThe inflammatory response begins when resident immune cells—such as mast cells, macrophages, and dendritic cells—detect damage-associated...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LTB4 Activates the MAP Kinase Pathway in Endothelial Cells to Cause Long-Lasting Neutrophil Tethering, MCP-1 and NO Releases.

Scandinavian journal of immunology·2026
Same author

Animal models in leukotriene research: Current insights into complex pathways and therapeutic intervention.

Pharmacology & therapeutics·2025
Same author

A helminth enzyme subverts macrophage-mediated immunity by epigenetic targeting of prostaglandin synthesis.

Science immunology·2024
Same author

Biosynthesis of resolvin D1, resolvin D2, and RCTR1 from 7,8(S,S)-epoxytetraene in human neutrophils and macrophages.

Proceedings of the National Academy of Sciences of the United States of America·2024
Same author

Determining site occupancy of acetaminophen covalent binding to target proteins in vitro.

Analytical science advances·2024
Same author

Microsomal glutathione transferase 1 controls metastasis and therapeutic response in melanoma.

Pharmacological research·2023

Related Experiment Video

Updated: May 7, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Targeting leukotriene B4 in inflammation.

Antonio Di Gennaro1, Jesper Z Haeggström

  • 1Karolinska Institutet, Department of Medical Biochemistry and Biophysics, Division of Chemistry 2 , Scheeles väg 2, Stockholm, S-171 77 , Sweden Jesper.Haeggstrom@ki.se.

Expert Opinion on Therapeutic Targets
|October 5, 2013
PubMed
Summary

Targeting leukotriene (LT) B(4) offers potential for treating inflammatory diseases. While LTB(4) inhibitors show promise in preclinical studies, clinical success remains elusive, necessitating further research into novel drug targets.

More Related Videos

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
08:33

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide

Published on: December 15, 2014

Related Experiment Videos

Last Updated: May 7, 2026

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin
13:45

Real-time Imaging of Leukotriene B4 Mediated Cell Migration and BLT1 Interactions with β-arrestin

Published on: December 23, 2010

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide
08:33

A Method for Generating Pulmonary Neutrophilia Using Aerosolized Lipopolysaccharide

Published on: December 15, 2014

Area of Science:

  • Biochemistry
  • Pharmacology
  • Immunology

Background:

  • Leukotriene B(4) (LTB(4)) is a potent pro-inflammatory mediator involved in leukocyte recruitment and activation.
  • Excessive LTB(4) contributes to chronic inflammatory conditions like asthma, rheumatoid arthritis, inflammatory bowel disease, and cardiovascular diseases.

Purpose of the Study:

  • To review recent findings on strategies targeting the 5-lipoxygenase pathway and LTB(4) receptors for inflammation treatment.
  • To discuss the application of these strategies in preclinical and clinical studies.

Main Methods:

  • Development of selective enzyme inhibitors for the 5-lipoxygenase pathway.
  • Design of antagonists for LTB(4) receptors.
  • Review of preclinical and clinical study data.

Main Results:

  • The 5-lipoxygenase pathway has yielded antileukotriene medications for asthma.
  • Specific targeting of LTB(4) has not yet achieved clinical success despite promising preclinical data.

Conclusions:

  • New opportunities for drug development targeting LTB(4)-mediated pathologies exist due to recent discoveries of enzyme structures and functions.
  • Further research is needed to translate promising preclinical findings into effective clinical treatments for LTB(4)-related diseases.